Edition:
United States

Endo International PLC (ENDP.O)

ENDP.O on Nasdaq

11.35USD
27 Jun 2017
Change (% chg)

-- (--)
Prev Close
$11.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,333,410
52-wk High
$24.93
52-wk Low
$9.70

Latest Key Developments (Source: Significant Developments)

Endo says reviewing FDA's request to withdraw Opana ER from market
Thursday, 8 Jun 2017 05:47pm EDT 

June 8 (Reuters) - Endo International Plc ::Endo response to june 8, 2017 FDA meeting related to opana® er.Endo international plc- "endo is reviewing request and is evaluating full range of potential options as we determine appropriate path forward".Endo - fda's request to withdraw opana er from market does not indicate uncertainty with product's safety or efficacy when taken as prescribed.  Full Article

Endo International reports entry of significant case management order in Mesh multidistrict litigation​
Wednesday, 7 Jun 2017 05:13pm EDT 

June 7 (Reuters) - Endo International Plc ::Endo International Plc - ‍announces entry of significant case management order in mesh multidistrict litigation​.  Full Article

Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada
Tuesday, 6 Jun 2017 02:59pm EDT 

June 6 (Reuters) - Veloxis Pharmaceuticals A/S ::Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada.Initial term of agreement is 15 years from effective date of agreement.Under terms of deal, co will get up-front payment and veloxis will supply envarsus xr at a pre-specified transfer price​.  Full Article

Endo reports Q1 GAAP loss per share $0.74
Tuesday, 9 May 2017 06:30am EDT 

May 9 (Reuters) - Endo International PLC : :Endo reports first-quarter 2017 financial results.Q1 adjusted earnings per share $1.23 from continuing operations.Q1 GAAP loss per share $0.74 from continuing operations.Q1 revenue $1.038 billion versus I/B/E/S view $1.02 billion.Q1 earnings per share view $1.10 -- Thomson Reuters I/B/E/S.Endo International PLC sees 2017 total revenues to be between $3.45 billion to $3.60 billion.Endo International PLC sees 2017 reported diluted gaap loss per share from continuing operations to be between $0.80 and $0.50.Endo International PLC sees 2017 adjusted diluted eps from continuing operations to be between $3.45 to $3.75.Endo International PLC - divestiture of its south african subsidiary, Litha Healthcare Group, to Acino Pharma AG is expected to close in Q2 of 2017.Endo International PLC - during first-quarter 2017, company recorded total combined pre-tax, non-cash impairment charges of $204 million.FY2017 earnings per share view $3.61 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.54 billion -- Thomson Reuters I/B/E/S.Endo International PLC - in April 2017, endo refinanced its $3.7 billion existing credit agreement.Endo International - recorded Q1 2017 restructuring cash charges of $15 million related to its restructuring program.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 09:36pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 07:20pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Endo International announces proposed private offering of senior secured notes
Monday, 10 Apr 2017 01:27pm EDT 

Endo International Plc : Endo International PLC announces proposed private offering of senior secured notes .Intends to use net proceeds to repay all outstanding loans, all other obligations under its existing credit facilities.  Full Article

Endo International sees total Q1 2017 revenues between $1,015 mln - $1,035 mln
Monday, 10 Apr 2017 08:02am EDT 

Endo International Plc : Endo International Plc - currently estimates total Q1 2017 revenues to be between $1,015 million and $1,035 million . Endo International Plc - Endo currently expects its Q1 2017 EBITDA from continuing operations to be between $440 million and $460 million .Q1 revenue view $1.02 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo International Plc announces plan to refinance existing credit agreement
Wednesday, 5 Apr 2017 07:30am EDT 

Endo International Plc : Endo International Plc announces plan to refinance existing credit agreement . Endo International Plc - new credit facilities are expected to be guaranteed by Endo and certain of its subsidiaries . Endo International Plc - transactions, if completed, would not be expected to materially change Endo's total debt . Endo International Plc - intends to use proceeds, together with net proceeds of other debt (which may be secured), to repay all outstanding loans and other obligations .Endo International Plc - intends to use net proceeds of new credit facilities, together with net proceeds of other debt to repay all outstanding loans.  Full Article

Endo International former CEO Rajiv De Silva's FY 2016 compensation $19.2 mln vs $10.9 mln in FY 2015
Wednesday, 22 Mar 2017 04:14pm EDT 

Endo International Plc :Endo international plc - former ceo rajiv de silva's fy 2016 total compensation was $19.2 million versus $10.9 million in fy 2015 - sec filing.  Full Article

More From Around the Web

Photo

U.S. asks drug maker Endo to withdraw opioid amid abuse crisis

WASHINGTON As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.